This is where you can learn about AOP-endorsed endeavors through other organizations. Because we feel strongly about these projects, we want to encourage our Advisors to get involved -- and reward them for doing so.
U.S. Patent Reform:
Article One is energizing the reform effort by providing additional patent validity information to the public and industry so that interested parties can assess the validity of important patents.
Article One also directly supports other reform efforts, including early review of pending applications submitted to the U.S. Patent Office. Article One joins the U.S. Patent Office and Congress in endorsing the important work of peertopatent.org, which invites the public to submit prior art for the patent applications posted on the peertopatent.org website. After reviewing the submitted art, Peer-to-Patent forwards the “top 10” references to the Patent Office for consideration as to whether a patent should be granted for that invention.
Acknowledging the critical work of Peertopatent.org, Article One encourages Advisors to participate in public-sector reform, offering increased Profit Sharing on articleonepartners.com when community members provide prior art that is accepted by peertopatent.org for submission to the Patent Office.
Here is a link to participate in Peer-to-Patent: www.peertopatent.org
When you complete the peertopatent.org process and are one of the top 10 prior art submitters so that your prior art is conveyed to the Patent Office for use in the application process, please send verification documents to us in a Request Reward section of our Site. Success at peertopatent.org earns you 250 Advisor Profit Sharing points.
Other Public Interest Projects:
Here is where you will find other projects of high value. If you come up with the solution to solve these world-wide problems, you earn 500 Advisor Profit Sharing points. Greenhouse gases: Virgin Earth Challenge to Save the Earth This research is for a commercially viable design which results in the removal of anthropogenic, atmospheric greenhouse gases so as to contribute materially to the stability of Earth's climate. Virgin Earth Challenge: http://www.virginearth.com Fragile X Research:
Fragile X syndrome is the most common inherited cause of mental impairment. It is an X-linked chromosomal disorder whose effects are typically more pronounced in boys than girls. Boys who have fragile X (and many girls who have it as well) suffer from intellectual disabilities that may cause mental retardation and in approximately one-third of the case, autism. Persons who have fragile X may also suffer from attention deficit disorders, speech and other developmental delays and unusual sensory responses to, e.g., various touch, auditory or visual stimuli. Fragile X syndrome is caused by a single abnormal gene, and researchers around the globe are working on treatments that could significantly improve the quality of life of persons who currently have the syndrome. Finding a treatment for fragile X may pave the way for treating other disorders including cases of autism regardless of whether they are caused by this gene. For more information please contact the National Fragile X foundation at www.fragilex.org.
GLUT1 Research
Among the many severe pediatric neurological disorders is a rare brain energy metabolic syndrome called glucose transporter deficiency syndrome (GLUT1). It means that an afflicted child's cells do not pick up and transport glucose to his brain properly. Glucose is the principal source of fuel to the brain. Children with this disorder have a myriad of physical and mental disabilities, ranging from mild to so severe that they cannot walk or talk. The only known treatment to date is a very restrictive diet called the ketogenic diet which is usually used for children with seizure disorders that do not benefit from conventional drugs. It is a treatment of last resort for them. For children with GLUT1, it is the only treatment that can control the seizures and hopefully help with providing energy to the brain. However, it is currently unknown how effective this treatment may be. Dr. DeVivo and his team of researchers at Columbia Presbyterian are working toward finding a more effective treatment or cure for GLUT1. If they can do so, then we would have the miracle that children with GLUT1 could lead lives free of neurological symptoms and disabilities. For children with GLUT1, it is a race against time. As they develop, their brains are developing without the necessary amount of energy to do so - clearly the sooner there is a more effective treatment, the better the odds are for all children with GLUT1. The primary support for the GLUT1 research effort has been a grant from the National Institute of Health (NIH). This year, the NIH notified the Colleen Giblin Laboratories, which are the only laboratories in the world that conduct GLUT1 research, that it will not continue funding the GLUT1 research. The Colleen Giblin Laboratories have only two appeals to try to reverse the NIH’s decision. In the meantime, this funding has stopped, and it is unlikely that the NIH will reverse its decision at the appeal level. This creates an immediate funding deficit as well as a threat to the future of this important life-altering research. This research is vital to diagnosing children with GLUT1 as well as finding a cure for the disorder. There are no other laboratories in the country or the world currently capable of providing the testing necessary to definitively diagnose GLUT1. Unless the GLUT1 research continues, a cure will not be attainable and innumerable future children may not be diagnosed in time to help them. More information is available at http://www.colleengiblinfound.org/Have you signed up yet to be awarded Points for your valuable contributions to public interest projects? You can do it here. |
